S
Steven C. Glossop
Researcher at AstraZeneca
Publications - 4
Citations - 251
Steven C. Glossop is an academic researcher from AstraZeneca. The author has contributed to research in topics: 2,3-Oxidosqualene & Lanosterol synthase. The author has an hindex of 4, co-authored 4 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-Fluoro-2-Methylpropyl)-3-Methyl-2, 3,4,9-Tetrahydro-1H-Pyrido[3,4-B]Indol-1-Yl)Phenyl)Acrylic Acid (Azd9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi,Robert Hugh Bradbury,Alfred A. Rabow,Richard A. Norman,Camila de Almeida,David M. Andrews,Peter Ballard,David Buttar,Rowena Callis,Gordon S. Currie,Jon Curwen,Christopher D. Davies,Craig S. Donald,Lyman Feron,H. Gingell,Steven C. Glossop,Barry R. Hayter,Syeed Hussain,Galith Karoutchi,Scott G. Lamont,Philip A. MacFaul,Thomas A. Moss,Stuart E. Pearson,Michael Tonge,Graeme Walker,Hazel M. Weir,Zena Wilson +26 more
TL;DR: The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described.
Journal ArticleDOI
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Sébastien L. Degorce,Barlaam Bernard Christophe,Elaine Cadogan,Allan Dishington,Richard Ducray,Steven C. Glossop,Lorraine A. Hassall,Franck Lach,Alan Lau,Thomas M. McGuire,Thorsten Nowak,Gilles Ouvry,Kurt Gordon Pike,Andrew G. Thomason +13 more
TL;DR: A novel series of 3-quinoline carboxamides discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase constitute excellent oral tools to probe ATM inhibition in vivo with overall ADME properties suitable for oral administration.
Journal ArticleDOI
Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles.
Brown George Robert,David M. Hollinshead,Stokes Elaine Sophie Elizabeth,David S. Clarke,M. A. Eakin,Alan J. Foubister,Steven C. Glossop,D. Griffiths,M. C. Johnson,Fergus McTaggart,Donald J. Mirrlees,Graham J. Smith,Robin Wood +12 more
TL;DR: Examination of HPLC lipid profiles from orally dosed rats showed cholesterol biosynthetic intermediates and whether cholesterol levels were reduced, and a new substituted quinuclidine pharmacophore 18a-c was rapidly found for the inhibition of OSC, and the most promising inhibitors were validated by the confirmation of potent OSC inhibition.
Journal ArticleDOI
A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase.
Brown George Robert,David M. Hollinshead,Stokes Elaine Sophie Elizabeth,David Waterson,David S. Clarke,Alan J. Foubister,Steven C. Glossop,Fergus McTaggart,Donald J. Mirrlees,Graham J. Smith,Robin Wood +10 more
TL;DR: A novel series of 4-piperidinopyrimidine OSC inhibitors showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase and may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.